Global Governance

Global governance refers to agreements among nations and/or statements and policies issued by international organizations. The most authoritative international agreement on human biotechnologies to date is the Council of Europe’s 1997 Convention on Human Rights and Biomedicine (also called the Oviedo Convention), a binding treaty that bans inheritable human genetic modification and human reproductive cloning. UNESCO, the European Parliament, the Group of Eight industrial nations, the World Health Organization, and the United Nations have also issued declarations or statements about human biotechnologies. 

 


Aggregated News

In August 2017, scientists reported that they had used the gene-editing tool CRISPR–Cas9 to correct a mutation in viable human embryos. The work is just one of countless applications of the technique, with which scientists hope to alter plants, animals...

Biopolitical Times

Public and policy conversations about heritable human genome editing often leave the impression that rules governing it are few and far between. Many news reports and scholarly articles present global governance as starting from a more or less blank slate; some also suggest that global agreement on this controversial issue would be unlikely. This view skims over some inconvenient facts, like the existence of the Oviedo Convention, a binding international treaty signed by 29 European countries, which prohibits heritable...

Biopolitical Times

Everyone knows, or thinks they know, that complex and fast-moving new biotechnologies inevitably outstrip legal regulation and ethical scrutiny. Surrogacy—the...

Biopolitical Times

The World Health Organization (WHO) on July 12 issued the results of what it describes as the “first broad, global...

Aggregated News

Aggregated News

Biopolitical Times

CGS-authored

Biopolitical Times

Global Governance of the New Human Biotechnologies

Submitted by admin on

The new human biotechnologies have potential for both great good and great harm. If used responsibly they could lead to important medical advances. If misused, however, they could exacerbate existing health disparities, lay a basis for new forms of discrimination and open the door to high-tech eugenic practices and ideologies that could undermine the foundations of civil society and indeed our common humanity. Many countries have begun developing national policies that address these challenges. However, some policies will need to be applied on a global level if they are to be meaningful. Without an international regulatory framework, regulatory arbitrage could prompt a race to the bottom regarding bioscience research and applications. It will not be easy to agree upon international accords, but they stakes are high and the coming decade affords a rare window of opportunity for pro-active policy development.

The session on November 4 will bring presenters and participants together to address foundational questions regarding the prospects of international governance of new human biotechnologies. What technologies and practices are of greatest concern? What is the current state of national and international policy addressing them? What intergovernmental, NGO, private sector other bodies and networks are in a position to play leadership roles? What sets of values might inform international accords? What are the strengths and weakness of various sorts of policy instruments? Are there alternatives to formal accords that might be more readily achieved and equally or more effective? And what action should be taken now if we want to see effective policies adopted over the coming decade?

Presenters:

  • George Annas, Boston University School of Public Health
  • Francis Fukuyama, Paul H. Nitze School of Advanced International Studies
  • Richard Hayes, Center for Genetics and Society
  • Chamundeeswari Kuppuswamy, University of Sheffield, United Kingdom


When: Nov. 4, 2:00-4:30 pm
Where: Rome Building 806
Johns Hopkins University School of Advanced International Studies (SAIS)
1619 Massachusetts Avenue NW, Washington, DC

Sponsors:

 

  • The Bernard Schwartz Forum on Constructive Capitalism
  • Center for Genetics and Society
  • Consortium of Policy, Science & Outcomes

Agenda
Summary of Discussion [PDF]
Background Reading
Speaker Bios
Participant List

 

Is Op-Ed
Off
Category
Date
2009-11-04T12:00:00
Pull Quote
Challenges and opportunities over the coming decade

Aggregated News

CGS-authored